Drug · CHEMBL976
PRAZIQUANTEL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PRAZIQUANTEL. Drugs and targets, record CHEMBL976. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL976
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Biltricide, Cesol, Cestocur, Cisticid, Cysticide, Praziquantel component of broadline, Praziquantel component of profender
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases15
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 15Source Open Targets
See all 15 diseasesTrials44
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02806232 | An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) | Phase 2 | 444 | 2019-11-20 | praziquantel | Its name | ClinicalTrials.gov |
| NCT00486863 | S. Japonicum and Pregnancy Outcomes | Phase 2 | 370 | 2014-02-07 | praziquantel | Its name | ClinicalTrials.gov |
| NCT03845140 | L-PZQ ODT in Schistosoma Infected Children | Phase 3 | 288 | 2024-03-21 | praziquantel | Its name | ClinicalTrials.gov |
| NCT00441285 | Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ) | Phase 2/3 | 156 | 2013-08-07 | praziquantel | Its name | ClinicalTrials.gov |
| NCT05323396 | HIV And Parasitic Infection (HAPI) Study | 120 | 2024-07-16 | praziquantel | Its name | ClinicalTrials.gov | |
| NCT03437447 | Praziquantel Bioequivalence Study | Phase 1 | 60 | 2019-09-18 | praziquantel | Its name | ClinicalTrials.gov |
| NCT02315352 | Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years | Phase 1 | 48 | 2017-03-06 | praziquantel | Its name | ClinicalTrials.gov |
| NCT02271984 | Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers | Phase 1 | 36 | 2018-01-03 | praziquantel | Its name | ClinicalTrials.gov |
| NCT04314037 | Bioequivalence Study of Coated Cesol Tablet Formulation Versus Biltricide | Phase 1 | 36 | 2021-08-13 | praziquantel | Its name | ClinicalTrials.gov |
| NCT02325713 | Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers | Phase 1 | 32 | 2017-02-23 | praziquantel | Its name | ClinicalTrials.gov |
1 to 10 of 44
See all 44 trialsComparisons in its trials10
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Praziquantel at 12-16 Weeks Gestation vs Placebo Control at 12-16 Weeks Gestation: Number of Participants Experiencing Fetal Loss by Abortion | 0 of 186 | 0 of 184 | 370 | NCT00486863 | Trial comparisons |
| Praziquantel at 12-16 Weeks Gestation vs Placebo Control at 12-16 Weeks Gestation: Number of Participants Reporting Serious Adverse Events Within 24 Hours of Dosing | 0 of 186 | 0 of 184 | 370 | NCT00486863 | Trial comparisons |
| Praziquantel at 12-16 Weeks Gestation vs Placebo Control at 12-16 Weeks Gestation: serious adverse events | 45 of 186 | 34 of 184 | 370 | NCT00486863 | Trial comparisons |
Praziquantel at 12-16 Weeks Gestation vs Placebo Control at 12-16 Weeks Gestation: Number of Subjects With Reduction in S. Japonicum Egg Counts From Screening to 22 Weeks Gestation of Greater Than 90 Percent | 157 of 184 | 92 of 184 | 368 | NCT00486863 | Trial comparisons |
| Praziquantel at 12-16 Weeks Gestation vs Placebo Control at 12-16 Weeks Gestation: Number of Participants Whose Pregnancy Resulted in a Live Birth | 181 of 183 | 181 of 183 | 366 | NCT00486863 | Trial comparisons |
| Praziquantel at 12-16 Weeks Gestation vs Placebo Control at 12-16 Weeks Gestation: Number of Participants With Pre-eclampsia | 0 of 181 | 0 of 183 | 364 | NCT00486863 | Trial comparisons |
| Praziquantel at 12-16 Weeks Gestation vs Placebo Control at 12-16 Weeks Gestation: Number of Participants Whose Infant Was Born With Congenital Anomalies | 1 of 181 | 1 of 181 | 362 | NCT00486863 | Trial comparisons |
| Cohort 1a: 4 to 6 Years L-PZQ ODT 50 mg/kg vs Cohort 1b: 4 to 6 Years Biltricide® 40 mg/kg: Cohort 1a and Cohort 1b: Number of Participants With Clinical Cure Determined by Kato-Katz Method | 86 of 98 | 39 of 48 | 146 | NCT03845140 | Trial comparisons |
| Cohort 2: 2 to 3 Years L-PZQ ODT 50 mg/kg vs Cohort 3: 3 to 24 Months L-PZQ ODT 50 mg/kg: Cohort 2 and Cohort 3: Number of Participants With Clinical Cure Determined by Kato-Katz Method | 27 of 29 | 17 of 18 | 47 | NCT03845140 | Trial comparisons |
| Albendazole + Praziquantel vs Albendazole + Placebo: serious adverse events | 2 of 16 | 2 of 16 | 32 | NCT00441285 | Trial comparisons |
Papers from its trials47
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL976
GET https://conductscience.org/api/drugs/v1/CHEMBL976/trials?page=2